Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5-6 Hours After Stroke Onset

NCT03578822 is registered in ClinicalTrials.gov with Tasly Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03578822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03578822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5-6 Hours After Stroke Onset
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 10, 2018
Completion date
March 1, 2020
Enrollment
149 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischaemic stroke